(secondQuint)A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder.

 Part A of the study is an open-label design with dosing of SAGE-217 for 14 days.

 Part B of the study is a randomized, double-blind, parallel-group, placebo-controlled design.

 Eligible subjects will be randomized to SAGE-217 or placebo for 14 days.

.

 A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder@highlight

This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in approximately 98 subjects diagnosed with moderate to severe Major Depressive Disorder.

